Literature DB >> 7603044

Matrix-associated latent TGF-beta with latent TGF-beta binding protein in the progressive process in adriamycin-induced nephropathy.

K Tamaki1, S Okuda, K Miyazono, M Nakayama, M Fujishima.   

Abstract

BACKGROUND: A progressive increase in latent transforming growth factor-beta (TGF-beta) secretion from diseased tissue was revealed in our previous work using adriamycin (ADR)-nephropathy (Kidney Int 45:525-36, 1994). Latent TGF-beta is composed of mature TGF-beta and latency-associated peptide (LAP) with or without latent TGF-beta-binding protein (LTBP). LTBP has been reported to contribute to either matrix-association or activation of latent TGF-beta. LTBP also seems to play a key role in the renal lesions of this model. The present study was designed to show the secretion of latent TGF-beta with LTBP and the location of LTBP in renal tissue in ADR-nephropathy. EXPERIMENTAL
DESIGN: The renal cortical tissue specimens were sampled at Weeks 4, 8, and 16 after the injection of ADR or saline (control) for cortical tissue culture and immunohistology. TGF-beta in the conditioned medium was assayed by immunoprecipitation and bioassay using mink lung epithelial cells. An immunohistochemical study was performed to examine the localization of LTBP, ED-1-positive macrophages, and extracellular matrix proteins including laminin, fibronectin, and collagen type I and type III.
RESULTS: A TGF-beta bioassay revealed a progressive increase in latent TGF-beta secretion from the cortex of diseased kidney. Free LTBP and LTBP-LAP complex with mature TGF-beta were immunoprecipitated by anti-LTBP Ab from the cortical culture medium. An immunohistochemical study using anti-LTBP Ab demonstrated that LTBP localization was restricted to the glomeruli and the arterioles in the control cortex. In the ADR rats at Week 4, a faint deposition of LTBP was observed in the interstitium around the glomeruli. At Week 8 or 16, LTBP was accumulated in the sclerosing glomeruli or fibrous interstitium, where ECM proteins and infiltrating ED-1-positive macrophages were intensely located.
CONCLUSIONS: Our results indicated that latent TGF-beta with LTBP was localized in association with the extracellular matrix in the sclerotic and fibrotic tissue in this model. Matrix-associated latent TGF-beta with LTBP may thus play an important role in the progressive process of glomerulosclerosis and interstitial fibrosis in ADR-nephropathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603044

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

Review 1.  The latent transforming growth factor beta binding protein (LTBP) family.

Authors:  R Oklü; R Hesketh
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

2.  Beta8 integrin binds Rho GDP dissociation inhibitor-1 and activates Rac1 to inhibit mesangial cell myofibroblast differentiation.

Authors:  Sujata Lakhe-Reddy; Shenaz Khan; Martha Konieczkowski; George Jarad; Karen L Wu; Louis F Reichardt; Yoshimi Takai; Leslie A Bruggeman; Bingcheng Wang; John R Sedor; Jeffrey R Schelling
Journal:  J Biol Chem       Date:  2006-05-11       Impact factor: 5.157

3.  Increased fibronectin expression in developing embryos is associated with abnormal notochord in the Adriamycin rat model.

Authors:  A Mortell; A M O'Donnell; S Giles; J Bannigan; P Puri
Journal:  Pediatr Surg Int       Date:  2004-02-18       Impact factor: 1.827

4.  Urinary Neutrophil Gelatinase-Associated Lipocalin to Monitor Lupus Nephritis Disease Activity.

Authors:  Hani Susianti; Jullyanny W Wijaya; Ati Rastini; Kusworini Handono; Atma Gunawan; Handono Kalim
Journal:  Biomark Insights       Date:  2015-09-06

5.  Effect of IgA aggregates on transforming growth factor-beta1 production in human mesangial cells and the intraglomerular expression of transforming growth factor-beta1 in patients with IgA nephropathy.

Authors:  Sang-Youb Han; Chun-Gyoo Ihm; Dae-Ryong Cha; Young-Sun Kang; Kum-Hyun Han; Hyoung-Kyu Kim; Jee-Young Han
Journal:  Korean J Intern Med       Date:  2005-03       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.